Danaher's Cytiva in U.S. Agreement to Expand Capacity for Covid-19 Vaccine-Related Items
October 13 2020 - 07:57PM
Dow Jones News
By Josh Beckerman
Danaher Corp.'s Cytiva unit will receive about $31 million under
an agreement with the U.S. Department of Health and Human Services
and Department of Defense to expand manufacturing capacity for
products used to make Covid-19 vaccines.
Cytiva will produce items including liquid and dry powder cell
culture media, cell culture buffers, mixer bags and XDR
bioreactors.
Cytiva will expand manufacturing capacity in its Massachusetts
facilities and create duplicate capabilities in its Utah
facilities, HHS said.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 13, 2020 19:42 ET (23:42 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Danaher (NYSE:DHR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Danaher (NYSE:DHR)
Historical Stock Chart
From Mar 2023 to Mar 2024